What Is TOREMIFEN CITRATE 60MG / ML | 60ML?
Toremifene belongs to the group of class non-steroidal selective estrogen receptor modulator (SERM). It is a chlorinated derivative of tamoxifen and shows equal efficacy in treating breast cancer. It exhibits estrogenic activity in bones and antiestrogenic action in breast tissues. As an FDA-approved drug, it is primarily indicated for the treatment of estrogen receptor-positive breast cancer and cancer of unknown receptor status in postmenopausal women. Furthermore, research indicates that it exerts a positive effect on osteoporosis and promotes fat loss. Currently, it is being studied for its effect on prostate cancer in men. At Pinnacle Peptides, toremifene for sale is exclusively available for research and experimentation.
Structure Of TOREMIFEN CITRATE 60MG / ML | 60ML
IUPAC Name: 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
Synonyms: Acapodene, Farestone, Z-Toremifene
Molecular Formula: C26H28ClNO
Molecular Weight: 406.0 g/mol
CAS number: 89778-26-7
PubChem CID: 3005573
Mechanism Of TOREMIFEN CITRATE 60MG / ML | 60ML
Toremifene is a synthetic derivative of tamoxifen and exhibits a similar mechanism of action. It shows antagonist action at estrogen receptors in breast tissues. It competes with estrogen and reversibly binds to the receptor, thus preventing ER from activating estrogen-response element on DNA. This, in turn, suppresses the proliferation of breast cancer cells. On the contrary, it exhibits agonism and mimics the action of endogenous estrogen in bone tissues, thus preventing bone resorption.
1. Bone Mineral Density
Research demonstrates that toremifene can enhance bone mineral density and reduce the risk of fractures. A randomized phase III clinical trial found that toremifene treatment resulted in a significant increase in bone mineral density at the hip and spine in prostate cancer patients undergoing androgen deprivation therapy. In another study, the drug’s use was associated with a 79.5% reduction in the risk of new vertebral fractures in men under 80 years of age, accompanied by a 7% decrease in bone loss and an increase in bone mineral density across various sites .
Additionally, a comparative study was designed to investigate the effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal women. Participants were randomized to receive either 20mg of tamoxifen or 40mg of toremifene for a year. The study concluded that tamoxifen significantly increases bone mineral density. Interestingly, toremifene did not exhibit a similar influence on bone mineral density in postmenopausal women .
Toremifene has also been investigated for its effect on dyslipidemia, characterized by abnormal lipid levels in the blood. Research shows that dyslipidemia is prevalent among postmenopausal women, making them susceptible to cardiovascular diseases. The literature demonstrates that toremifene might improve serum lipid levels. One study found that toremifene significantly decreased LDL cholesterol (bad cholesterol) and increased HDL-C (good cholesterol) levels .
Similarly, androgen deprivation therapy raises serum lipid levels and increases the risk of coronary artery disease and myocardial infarction. Research conducted on men with prostate cancer undergoing antiandrogen treatment found that toremifene decreased total cholesterol, triglycerides and LDL-C levels .
3. Comparison with Tamoxifen
Research shows that toremifene and tamoxifen exhibit equivalent efficacy for the treatment of breast cancer in postmenopausal women. Analysis of nine phase III randomized trials indicates that toremifene has the same effect as tamoxifen. However, it exhibits a slightly better side effect profile and is less likely to cause uterine neoplasm .
The pharmacokinetic characteristics (absorption, distribution, metabolism and elimination) of both drugs vary as a result of slight differences in structure. Tamoxifen is a prodrug that is converted into its active metabolite through transformation by CYP2D6. On the other hand, toremifene doesn’t need such enzymes for its therapeutic action. These findings suggest that toremifene might serve as an alternative option for patients with CPY2D6 polymorphism .
4. Prevention of Prostate Cancer
Research shows that toremifene can prevent prostate cancer in men who are at high risk. One study found a decrease in the incidence of prostate cancer in men with prostatic intraepithelial neoplasia (PIN) who were treated with toremifene. Prostatic intraepithelial neoplasia is characterized by pathological changes in the cell lining of the prostate gland ducts, representing precursors to prostate cancer. .
Toremifene is a non-steroidal selective estrogen receptor modulator (SERM). It is used for the treatment of hormone-sensitive breast cancer in postmenopausal women. Furthermore, research suggests that it can improve serum lipid profile. Improve bone mineral density and lower the risk of prostate cancer. At Pinnacle Peptides, toremifene purchase is only available for research and educational institutions. Only buy toremifene if you are an authorized researcher.
- Smith, M.R., et al., Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol, 2008. 179(1): p. 152-5.
- Smith, M.R., et al., Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology, 2011. 186(6): p. 2239-2244.
- Marttunen, M.B., P.i. Hietanen, A. Tiitinen, and O. Ylikorkala, Comparison of Effects of Tamoxifen and Toremifene on Bone Biochemistry and Bone Mineral Density in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism, 1998. 83(4): p. 1158-1162.
- Tominaga, T., et al., Effects of Toremifene and Tamoxifen on Lipid Profiles in Post-menopausal Patients with Early Breast Cancer: Interim Results from a Japanese Phase III Trial. Japanese Journal of Clinical Oncology, 2010. 40(7): p. 627-633.
- Smith, M.R., et al., Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol, 2008. 26(11): p. 1824-9.
- Mustonen, M.V., S. Pyrhönen, and P.L. Kellokumpu-Lehtinen, Toremifene in the treatment of breast cancer. World J Clin Oncol, 2014. 5(3): p. 393-405.
- Li, X., et al., Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer research and treatment, 2023.
- Price, D., et al., Toremifene for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia: Results of a Double-Blind, Placebo Controlled, Phase IIB Clinical Trial. The Journal of Urology, 2006. 176(3): p. 965-971.
What is Toremifene?
Toremifene is a medication belonging to the class of drugs known as selective estrogen receptor modulators (SERMs). It is largely employed in the management of postmenopausal women's breast cancer. Toremifene works by preventing the effects of estrogen in specific tissues, which prevents the proliferation of breast cancer cells that are susceptible to estrogen. It can be used in both early and advanced stages of breast cancer and is administered as an alternative to other SERMs like tamoxifen. Toremifene is also being investigated for its ability to prevent osteoporosis because it has been demonstrated to help postmenopausal women retain bone density.
The selective estrogen receptor modulator (SERM) toremifene has been thoroughly studied. Here we provide an overview of the research conducted on Toremifene, highlighting its use in breast cancer treatment, its potential applications in other conditions, and emerging areas of investigation.
Breast Cancer Treatment:
The use of toremifene in treating breast cancer is a prominent field of research. Studies have shown that it is helpful for postmenopausal women with both early-stage and advanced breast cancer. By preventing estrogen's actions, toremifene prevents the proliferation of breast cancer cells that are susceptible to estrogen. Its effectiveness, safety profile, and potential for usage as a substitute for other SERMs, such as tamoxifen, are all subjects of research. Furthermore, ongoing trials investigate Toremifene's role in combination therapies and its impact on disease recurrence and survival rates.
Prevention and Risk Reduction:
Researchers have also looked into toremifene's potential for preventing breast cancer and lowering the probability of the illness returning. Clinical trials are looking into its application in high-risk groups, such as women with a family history of breast cancer or specific genetic abnormalities. Toremifene seeks to lower the risk of breast cancer development or postpone its initiation in people at risk by targeting estrogen receptors. Its potential as a preventative tool and risk-reduction tactic is highlighted by these research.
Studies on toremifene's effects on osteoporosis prevention have been conducted in addition to its use in the treatment of breast cancer. Toremifene, a SERM, has demonstrated potential in preserving bone density and lowering the risk of fractures in postmenopausal women. Studies look into how it affects fracture rates, markers of bone turnover, and bone mineral density. The findings reveal prospective substitute therapies for postmenopausal osteoporosis and advance our knowledge of toremifene's function in maintaining bone health.
Emerging Areas of Investigation:
Scientists are also looking into how toremifene might be used for other ailments. Its effectiveness in treating prostate cancer, endometrial cancer, and other hormone-sensitive cancers has been investigated in preclinical research. Toremifene's capacity to alter estrogen receptors provides doors for research into how effective it might be in treating certain tumors. Studies have also looked at its effects on cardiovascular health, cognitive function, and quality of life in breast cancer survivors, emphasizing its wider impact on patient well-being beyond cancer therapy alone.
Where to Buy Toremifene
If you are looking to buy toremifene online for laboratory use, then Pinnacle Peptides is the supplier you can trust. We provide high-quality toremifene for sale that is ideal for scientific research with their trustworthy and respectable service. To assure purity and effectiveness, their products go through extensive testing. We offer top-notch toremifene to researchers since they recognize how important it is for studies to produce accurate and trustworthy results. Pinnacle Peptides has you covered whether you're researching breast cancer treatment, prevention, or looking into its possibilities in other ailments. Trust our expertise and purchase Toremifene from our online store to support your research endeavors.
The products we offer are intended for laboratory research use only. In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products. These chemicals are NOT intended to use as food additives, drugs, cosmetics, household chemicals or other inappropriate applications. The listing of a material on this site does not constitute a license to its use in infringement of any patent. All of the products will be handled only by qualified and properly trained professionals. All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following: Government regulations regarding the use of and exposure to all products. The health and safety hazards associated with the handling of the products they purchase. The necessity of adequately warning of the health and safety hazards associated with any products. Pinnacle Peptides and pinnaclepeptides.com reserves the right to limit and/or deny sales of products to any unqualified individuals if we have reason to believe that misuse will occur.